HALO
MRK
Halozyme’s patent play just got teeth
Halozyme says the specialized Dutch patent court in The Hague sided with it, finding Merck infringed one of its MDASE patents, EP 2,797,622. The result: a court-ordered injunction that tells Merck’s European hub, MSD BV, to stop manufacturing and moving Keytruda SC across a chunky list of markets.
What gets blocked?
The injunction covers Belgium, Denmark, France, Ireland, Italy, Sweden, Switzerland and the Netherlands — basically a lot of the European table setting for this product. MSD BV is also barred from helping affiliates keep the alleged infringement going by leaning on its European marketing authorization.
Why investors should care
This isn’t just legal paper shuffling. Keytruda is already a giant franchise for Merck, and Keytruda SC is the subcutaneous version that could make administration easier and widen the moat. If Halozyme can keep squeezing on patent rights, it may preserve royalty leverage, negotiation power, or both.
Big picture
For Halozyme, this is the kind of courtroom win that can travel well on a slide deck. For Merck, it’s another reminder that even blockbuster drugs can hit potholes when patents get cranky.